A0980
AM281
≥98% (HPLC)
别名:
1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide, AM 281
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C21H19Cl2IN4O2
CAS Number:
分子量:
557.21
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white
溶解性
DMSO: >6 mg/mL
H2O: insoluble
储存温度
2-8°C
SMILES字符串
Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCOCC4
InChI
1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)
InChI key
AJFFBPZYXRNAIC-UHFFFAOYSA-N
基因信息
rat ... Cnr1(25248)
应用
AM281 has been used as a cannabinoid 1 receptor antagonist:
- to study its effects on memory deficit following naloxone-precipitated morphine withdrawal in mice
- to study the role of CB1 receptor system in modulating acetaldehyde-induced effects in rats during the extinction-, relapse-, and conflict-experiments
- to study its effect on scopolamine-induced memory deficit using object recognition paradigm
- to block synthetic cannabinoid (HU210)-induced analgesia in the ventrolateral orbital cortex (VLO) to evaluate the effect of CB1 receptors on the VLO modulation of pain
生化/生理作用
AM281 is less lipophilic compared to its analog SR 141716A, a cannabinoid receptor antagonist. AM281 may prevent memory deficit post morphine withdrawal by inhibiting cannabinoid receptors in mice.
Potent and selective CB1 cannabinoid receptor antagonist/inverse agonist
特点和优势
This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
警示用语：
Danger
危险分类
Acute Tox. 2 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Golnaz Vaseghi et al.
Basic & clinical pharmacology & toxicology, 111(3), 161-165 (2012-03-21)
Morphine withdrawal leads to the activation of endocannabinoid system and cognitive deficits. The aim of this study was to evaluate the effects of AM281, a cannabinoid antagonist/inverse agonist, on memory deficit following naloxone-precipitated morphine withdrawal in mice. Male mice were
Yuwei Wu et al.
Neuroscience letters, 736, 135286-135286 (2020-08-04)
The prefrontal ventrolateral orbital cortex (VLO) is involved in antinociception. It has been found that dopamine receptors, adrenoceptors, serotonin receptors and μ-opioid receptors are involved in this effect through direct/indirect activation of the VLO output neurons. However, the effect of
Francisco Molina-Holgado et al.
Molecular and cellular neurosciences, 28(1), 189-194 (2004-12-21)
Cannabinoids (CBs) are neuroprotective in vivo and in vitro, but the mechanisms of their actions are unknown. The aim of this study was to elucidate the signaling pathways that mediate the protective effect of CBs on primary cultured neurons. The
A N Gifford et al.
Neuroscience letters, 238(1-2), 84-86 (1998-02-17)
The SPECT ligand AM 281, a less lipophilic analog of the cannabinoid receptor antagonist SR 141716A, robustly potentiated electrically-evoked release of acetylcholine from superfused hippocampal slices and prevented the inhibition of acetylcholine release by the cannabimimetic drug WIN 55212-2. These
Edgar Alfonso Romero-Sandoval et al.
Molecular pain, 5, 25-25 (2009-05-30)
Cannabinoid receptor type 2 (CBR2) inhibits microglial reactivity through a molecular mechanism yet to be elucidated. We hypothesized that CBR2 activation induces an anti-inflammatory phenotype in microglia by inhibiting extracellular signal-regulated kinase (ERK) pathway, via mitogen-activated protein kinase-phosphatase (MKP) induction.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持